NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDDupilumab Dupixent®
(For severe asthma with type 2 inflammation) 		Respiratory system, Allergen Immunotherapy, 03.04.02
REDDupilumab Dupixent®
(For severe atopic eczema) 		Skin, Drugs affecting the immune response, 13.05.03
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Dupilumab Dupilumab Nose, Immunosuppressants, Interleukin Inhibitors
Nasal Inflammation, Nasal Polyps And Rhinitis
Dupilumab Dupilumab Respiratory System, Immunosuppressants, Interleukin Inhibitors
Airways Disease, Obstructive
Dupilumab Dupilumab Skin, Immunosuppressants, Interleukin Inhibitors
Inflammatory Skin Conditions, Eczema And Psoriasis
Dupilumab Dupilumab Skin, Immunosuppressants, Interleukin Inhibitors
Pruritus
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
MHRA DSU Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management
MHRA DSU: Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management
NICE TA1134: Dupilumab for treating severe chronic rhinosinusitis with nasal polyps
NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis
NICE TA751 Dupilumab for treating severe asthma with type 2 inflammation
NICE TA955: Dupilumab for treating moderate to severe prurigo nodularis (NOT RECOMMENDED)